跳至主要内容
临床试验/NCT05172284
NCT05172284尚未招募不适用

Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases (IMIDs) REMIND Study

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2022年2月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
2,000
试验地点
1
主要终点
Registry of ImmuNe-mediated inflammatory Diseases (IMIDs)

研究概览

简要总结

Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies. This aim is achieved by evaluating the achievement of PASI 50 and PASI 75 scores at week 16 from the start of treatment.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with a diagnosis of IMID.
  • Patients of any age, including minors.
  • Patients treated with approved medications for the condition in question and/or phototherapy.
  • Patients who agree to sign informed consent.

排除标准

  • Patients without a diagnosis of IMID.
  • Patients who do not consent to sign informed consent.

结局指标

主要结局

Registry of ImmuNe-mediated inflammatory Diseases (IMIDs)

时间窗: 15 years

Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies.

次要结局

  • PASI 75(15 years)
  • PASI 50(15 years)

研究者

发起方
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验